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HNF4a b s t r a c t
The aberrant regulation of many related genes is involved in the development and progression of
gastric carcinoma. In the present study, we show that mRNA and protein levels of FOXO6 are upreg-
ulated in gastric cancer tissues. Forced overexpression of FOXO6 promotes gastric cancer cell prolif-
eration, while knockdown of FOXO6 expression inhibits proliferation. We show that ectopic FOXO6
expression induces the expression of C-myc. Furthermore, we found that FOXO6 physically interacts
with the transcription factor hepatic nuclear factor 4 (HNF4) in gastric cancer cells. FOXO6 induces
C-myc expression by associating to HNF4 and mediating histone acetylation, and the dissociation of
HDAC3 from the promoter of the C-myc gene. Therefore, our results suggest a previously unknown
FOXO6/HNF4/C-myc molecular network controlling gastric cancer development.
Structured summary of protein interactions:
FOXO6 physically interacts with HNF4 by anti bait coimmunoprecipitation (View Interaction: 1, 2)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer has become the fourth most common malig-
nancy and the second cause of death [1,2]. Numerous studies indi-
cate that the development and progression of gastric cancer arises
via miss-regulation of many related genes such as C-myc, p53 and
PTEN [3–5]. However, the regulatory mechanisms remain poorly
understood. Therefore, discovery of critical carcinogenic pathways
may be beneﬁcial for the identiﬁcation of new therapeutic targets
for gastric cancer.
The FOXO family of Forkhead transcription factors has attracted
a lot of interest because of its conserved role in the regulation of
many cellular processes, including proliferation, apoptosis, differ-
entiation and metabolic pathways [6,7]. Mammals have four FOXO
isoforms (FOXO 1, FOXO3, FOXO4, and FOXO6). Growing evidence
suggested that FOXO1 could inhibit cell proliferation in many types
of tumor cells, including gastric cancer cells [8,9]. For example,
FOXO1 can lead to cell-cycle arrest through up-regulation of the
cyclin-dependent kinase (CDK) inhibitors, p27and p21, anddown-regulation of the cell-cycle regulator Cyclin D1 [10–12].
Forkhead box protein O 6 (FOXO6) is also a member of the FOXO
family, however, its biological functions were very limited. Previ-
ous studies have shown that FOXO6 plays an important role in
the regulation of hepatic glucose homeostasis and synaptic func-
tion in mice [13,14]. Interestingly, the clinical relevance of FOXO6
in cancer biology was not fully understood. In the present study,
we found that FOXO6 expression was up-regulated in gastric can-
cer tissues. Overexpression of FOXO6 promoted proliferation of
gastric cancer cells. In addition, we discovered that FOXO6 played
a role in gastric cancer development through regulation of C-myc
expression. Identiﬁcation the roles of FOXO6 might help to further
understand the pathological mechanisms of gastric cancer cell ini-
tiation and proliferation.
2. Materials and methods
2.1. Tissue samples
25 paired primary gastric cancer tissues and normal gastric tis-
sues were collected from routine therapeutic surgery at our
department. All samples were obtained with informed consent
and approved by Rui-Jin Hospital, Shanghai Jiao Tong University
School of Medicine.
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Gastric cancer cell lines (SNU-16 and NCI-N87) used were pur-
chased from The Cell Bank of Type Culture Collection of Chinese
Academy of Sciences (CAS, Shanghai), and cultured in Dulbecco
modiﬁed Eagle’s medium (DMEM; Sigma, St. Louis, MO, USA) sup-
plemented with 10% fetal calf serum, 100 IU/ml penicillin and
100 mg/ml streptomycin. Cultures were maintained at 37 C in a
humidiﬁed atmosphere with 5% CO2.
2.3. Expression plasmids and retro-viruses
Wild-type FOXO6 and FOXO6 with DNA binding domain dele-
tion (FOXO6-DBD del) plasmids were purchased from Genechem
(Shanghai, China). HNF4 expression plasmids were purchased from
Bioyare Technology (Shanghai, China). Viral supernatants were
produced in HEK293T cells co-transfected with the pBabe-puro
constructs and packaging vectors GAGPOL and VSV-G (Clontech).
Viral supernatants were collected 48 h after transfection, ﬁlter-
sterilized, and stored at 80 C.
2.4. Promoter construction and Luciferase assays
Human C-myc promoter was cloned from the human genomic
DNA and inserted into pGL4.15 vector (Promega). Mutant HNF4
binding motif was generated using a PCR mutagenesis kit (Toyobo)
with a primer (mutation sites underlined): 50-TTATCAGTCCCAGC-
TAGCAG-30. For luciferase reporter assays, cells were seeded into
24-well plates and transfected with 200 ng promoter plasmids by
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s
instructions. pRL-SV40 (Promega) expressing renilla luciferase was
used to normalize the luciferase activities, which were measured
using the Dual Luciferase Reporter Assay System (Promega, USA).
2.5. siRNA, RNA extraction and Real-time analysis
Cells were seeded into 6-well plates and then transfected with
10 nM siGENOME non-targeting siRNA, human FOXO6 or HNF4
(Dharmacon, USA). Total RNAs were isolated from tissues or cells
by TRIzol reagent (Invitrogen, USA), and reverse transcriptions
were performed by Takara RNA PCR kit (Takara, China), following
the manufacturer’s instructions. In order to determine the tran-
scripts of the interest genes, Real-time PCR was performed using
a SYBR Green Premix Ex Taq (Roche, Switzerland) on Light Cycler
480 (Roche). b-Actin gene was used as an internal control. The
primers used were as following: FOXO6 (Forward: 50-
GGCCGCGCTCGTGTACC-30; Reverse: 50-TACACGAGCGCGGCCG-30);
C-myc (Forward: 50-GGCTCCTGGCAAAAGGTCA-30; Reverse: 50-CT
GCGTAGTTGTGCTGATGT-30); CylinD1 (Forward: 50-TGGAGCCCGTG
AAAAAGAGC-30; Reverse: 50-TCTCCTTCATCTTAGAGGCCAC-30); Cy-
linD2 (Forward: 50-ACCTTCCGCAGTGCTCCTA-30; Reverse: 50-CCCA
GCCAAGAAACGGTCC-30); CylinE (Forward: 50-ACTCAACGTGCA
AGCCTCG-30; Reverse: 50-GCTCAAGAAAGTGCTGATCCC-30); Cdc25A
(Forward: 50-GTGAAGGCGCTATTTGGCG-30; Reverse: 50-TGGTTG
CTCATAATCACTGCC-30); HNF4 (Forward: 50-CGAAGGTCAAGCTAT-
GAGGACA-30; Reverse: 50-ATCTGCGATGCTGGCAATCT-30); b-actin
(Forward: 50-CATGTACGTTGCTATCCAGGC-30; Reverse: 50-CTCCT
TAATGTCACGCACGAT-30)
2.6. Western blot
Cells or tissues were harvested and lysed with ice-cold lysis buf-
fer (50 mM Tris–HCl, pH 6.8, 100 mM 2-ME, 2% w/v SDS, 10% glyc-
erol). After centrifugation at 20000g for 10 min at 4 C, proteins
in the supernatants were quantiﬁed and separated by 10% SDS–
PAGE, transferred to NC membrane (Amersham Bioscience, Buck-inghamshire, U.K.). After blocking with 10% non-fat milk in PBS,
membranes were immunoblotted with antibodies as indicated, fol-
lowed by HRP-linked secondary antibodies (Cell Signaling). The
signals were detected by SuperSignal West Pico Chemiluminescent
Substrate kit (Pierce, Rockford, IL, USA) according to manufac-
turer’s instructions. Anti-b-actin antibody was purchased from
(USA). Anti-FOXO6, anti-FOXO1, anti-C-myc, anti-Cyclin D1, anti-
Cyclin D2, anti-Cyclin E, anti-Cdc25A and anti-HNF4 antibodies
were from Abcam (USA).
2.7. ChIP assays
Chromatin immunoprecipitation (ChIP) assay kits were used
(Upstate, USA). In short, Cells or tissues were ﬁxed with 1% formal-
dehyde to cross-link the proteins and DNA, followed by sonication
in an ultrasound bath on ice. DNA was sheared to fragments at
200–1000 bp using sonication. The chromatin was then incubated
and precipitated with the indicated antibodies. The immunopre-
cipitated DNA fragments were detected using Real-time PCR anal-
ysis. The primer used in ChIP assays is listed as following: Forward
(50-TGAGTCTCCTCCCCACCT-30) and Reverse (50-GTCCAGACCCT
CGCATTA-30).
2.8. Statistical analysis
All the cellular experiments were performed three or four times.
Data are presented as mean ± SEM. Statistical differences were
determined by a two-tailed t test. Statistical signiﬁcance is dis-
played as ⁄(P < 0.05), ⁄⁄(P < 0.01) or ⁄⁄⁄(P < 0.001).3. Results
3.1. Up-regulation of FOXO6 in gastric cancer tissues
At theﬁrst, FOXO6mRNAandprotein levelswere compared in 25
paired gastric cancer tissues and normal gastric tissues. We found
that FOXO6mRNAexpressionwas signiﬁcantly up-regulated in can-
cer tissues (Fig. 1A). Besides,Westernblot also showed the increased
protein contents of FOXO6 in four pairs of cancer samples (Fig. 1B).
3.2. FOXO6 regulates cell proliferation in gastric cancer cells
To further determine the potential effects of FOXO6 in gastric
cancer cells, we introduced SNU-16 cells with retro-viruses con-
taining empty vector (Ctrl) or FOXO6 (Fig. 2A). As shown in
Fig. 2B, FOXO6 overexpression led to a signiﬁcant increase in cell
number of SNU-16 cells (Fig. 2B). Moreover, bromodeoxyuridine
(BrdU) analysis also suggested that forced FOXO6 overexpression
promoted cell proliferation (Fig. 2C). Indeed, FOXO6 overexpress-
ing SNU-16 cells had a signiﬁcantly lower percentage of cells in
the G1/G0 phase and increased percentage of cells in the S phase,
compared to empty vector-transfected cells (Fig. 2D). Next, SNU-
16 cells were transfected with small interfering RNA (siRNA) tar-
geting FOXO6 to knockdown endogenous FOXO6 expression
(Fig. 2E and F). As a result, down-regulation of FOXO6 led to a
marked decrease in cell number and proliferation in SNU-16 cells
(Fig. 2G and H). Additionally, silencing of FOXO6 signiﬁcantly in-
creased the percentage of cells in the G0/G1 phase and decreased
the percentage of cells in the S phase (Fig. 2I).3.3. FOXO6 overexpression induces C-myc transcription in gastric
cancer cells
As described above, FOXO6 plays a critical role in the prolifera-
tion of gastric cancer cells. In agreement, we further found that a
Fig. 2. FOXO6 promotes cell proliferation in SNU-16 cells. (A) FOXO6expression was determined by Western blot in SNU-16 cells transfected with retro-viruses expressing
empty vector (Ctrl) or FOXO6. (B) The growth curve of SNU-16 cells transfected with empty vector (Ctrl) or FOXO6. ⁄P < 0.05 compared with empty vector (Ctrl). (C) The cell
proliferative potential (BrdU) was determined in SNU-16 cells transfected with empty vector (Ctrl) or FOXO6. A450 absorption was assayed after transfection for 24 h.
⁄⁄P < 0.01 compared with empty vector (Ctrl). (D)The cell cycle phase of SNU-16 cells transfected with empty vector (Ctrl) or FOXO6 were analyzed by ﬂow cytometry. Cells
were labeled for 15 min with PI and immediately analyzed by ﬂow cytometry. Histograms represent the percentage of cells in each phase of the cell cycle (G0/G1, S and G2/
M). (E and F) mRNA and protein levels of FOXO6 expression was determined by Real-time PCR (E) andWestern blot (F) in SNU-16 cells transfected with siRNA oligos targeting
FOXO6 (FOXO6-1, FOXO6-2) or scramble siRNA (Ctrl). Cells were seeded into 6-well plates and transfected with siRNA for 24 or 48 h to harvest RNA or proteins, respectively.
⁄⁄P < 0.01 compared with scramble siRNA oligos (Ctrl). (G) The growth curve of SNU-16 cells transfected with transfected with siRNA oligos targeting FOXO6 (FOXO6-1,
FOXO6-2) or scramble siRNA (Ctrl). ⁄⁄P < 0.01 compared with control siRNA oligos (Ctrl). (H) The cell proliferative potential (BrdU) was determined in SNU-16 cells as
indicated. ⁄P < 0.05, ⁄⁄P < 0.01 compared with control siRNA oligos (Ctrl). (I) The cell cycle phase of SNU-16 cells transfected with siRNA oligos targeting FOXO6 (FOXO6-1,
FOXO6-2) or scramble siRNA (Ctrl) were analyzed by ﬂow cytometry.
Fig. 1. Up-regulation of FOXO6 in lung cancer tissues and cell lines. (A and B) mRNA and protein levels of FOXO6 were analyzed by Real-time PCR (A) and Western blot (B) in
normal tissues (normal) or gastric cancer tissues. ⁄⁄⁄P < 0.001, compared with normal tissues.
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SNU-16 cells overexpressing FOXO6, including Cyclin D1 and D2,
Cyclin E and Cdc25A (Fig. 3A and B). Consistently, FOXO6 inhibition
by siRNA oligos led to a decreased expression of these genes(Fig. 3C and D). Previous studies have focused on C-myc’s effect
on these regulatory proteins of the transition of the cell cycle
[15,16], which prompted us to investigate whether C-myc could
be a target gene of FOXO6. As shown in Fig. 3E and F, overexpres-
Fig. 3. FOXO6 up-regulates c-myc expression in SNU-16 cells. (A and B) mRNA (A) and protein (B) levels of cell-cycle regulatory genes were analyzed by Real-time PCR or
Western blot in SNU-16 cells transfected with empty vector (Ctrl) or FOXO6 for 24 or 48 h, respectively. ⁄P < 0.05, ⁄⁄P < 0.01 compared with empty vector (Ctrl). (C and D)
mRNA (C) and protein (D) levels of cell-cycle regulatory genes were analyzed by Real-time PCR or Western blot in SNU-16 cells transfected with siRNA oligos targeting FOXO6
(FOXO6-1) or scramble siRNA (Ctrl) for 24 or 48 h, respectively. ⁄P < 0.05, ⁄⁄P < 0.01 compared with scramble siRNA (Ctrl). (E and F) mRNA (E) and protein (F) levels of C-myc
were determined in SNU-16 cells administrated with retro-viruses expressing empty vector (Ctrl) or FOXO6 for 24 or 48 h, respectively. ⁄⁄⁄P < 0.001 compared with empty
vector (Ctrl). (G and H) mRNA (G) and protein (H) levels of c-myc in SNU-16 cells transfected with siRNA oligos targeting FOXO6 (FOXO6-1) or scramble siRNA (Ctrl) for 24 or
48 h, respectively. ⁄⁄P < 0.01 compared with scramble siRNA (Ctrl).
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trast, FOXO6 depletion dramatically led to a reduction of C-myc
contents (Fig. 3G and H). Moreover, this regulation was also ob-
served in another gastric cancer cell, NCI-N87 cells (Supplementary
Fig. 1A–D), suggesting that FOXO6 was an up-stream regulator of
C-myc transcription.
3.4. FOXO6 up-regulates C-myc promoter activity through an HNF4
binding site
To delineate the regulatory pathway from FOXO6 to C-myc
expression, we generated luciferase reporters fused to the pro-
moter region of C-myc (positions 1200 to +1). We then tested
whether FOXO6 induced activity of C-myc promoter fused lucifer-
ase reporter. When FOXO6 was overexpressed, the activity of C-
myc was markedly higher (Fig. 4A). Unexpectedly, FOXO6 with
deletion of DNA binding domain (FOXO6-DBD- del) could also
up-regulate C-myc promoter activity, to the similar extent with
wild-type FOXO6 (Fig. 4A). Indeed, overexpression of FOXO6-
DBD-del also increased C-myc mRNA and protein levels in SNU-
16 cells (Fig. 4B and C), suggesting that FOXO6 may regulate C-
myc transcription through a transactivation mechanism. Consis-
tently, FOXO6-DBD-del overexpression also promoted cell prolifer-
ation in SNU-16 cells using BrdU assays (data not shown).
Next, through serial deletion of C-myc promoter, we deﬁned a
minimal FOXO6-responsive region (254–246 bp upstream of the
transcriptional start site) that contained a consensus binding sites
for HNF4 (Fig. 4D). Indeed, overexpression of HNF4 increased lucif-
erase activity of wild-type C-myc promoter, but not a mutant C-
myc promoter carrying an alteration in the HNF4 binding site
(Fig. 4E). Besides, the binding of HNF4 to this region was also con-
ﬁrmed by chromatin immunoprecipitation (ChIP) assays (Supple-
mentary Fig. 2A). Moreover, stimulation by FOXO6 was also not
observed in this mutant promoter (Fig. 4F) or when HNF4 was
knocked down (Supplementary Figs. 2B and C and 4G). Consis-
tently, the induction of endogenous C-myc expression by the over-expression of FOXO6 was abrogated by knockdown of HNF4
(Fig. 4H and I).
3.5. FOXO6 cooperates HNF4 to trans-activate C-myc expression
Next, we used coimmunoprecipitation to assess whether the
ability of FOXO6 to enhance HNF4-dependent C-myc expression
is linked to a physical interaction between FOXO6 and HNF4. When
a nuclear fraction isolated from gastric cancer cells was immuno-
precipitated with an antibody against FOXO6, HNF4 was detected
in the immunoprecipitate (Fig. 5A). In the reciprocal experiment,
endogenous HNF4 was also able to co-precipitate FOXO6
(Fig. 5B). Besides, we found that the AF-2 domain of HNF4 was re-
quired for this interaction.
To further explore the molecular mechanism by which FOXO6
induces C-myc expression, we measured the amount of FOXO6
and HNF4 associated with the C-myc promoter by ChIP assays.
Our results revealed that FOXO6 was associated with the C-myc
promoter, and this association was reduced when HNF4 was
knocked down (Fig. 5C). Notably, the association of HNF4 with
the C-myc promoter was substantially increased when FOXO6
was overexpressed but markedly reduced in FOXO6 deﬁciency
cells (Fig. 5D and E). Sequential ChIP experiments indicated that
FOXO6 and the HNF4 complex reside together on the C-myc pro-
moter (Supplementary Fig. 3). Because HNF4 belongs to a family
of nuclear receptors, which mediated activation of downstream
target genes involves dissociation of the HDACs-containing tran-
scription corepressor complex from the promoter [17,18]. We
examined the association of HDACs with the C-myc promoter in
the presence and absence of FOXO6. The association of HDAC3
(Fig. 5F and G), but not HDAC1 or HDAC2 (data not shown), with
the C-myc promoter was dramatically reduced in cells over-
expressing FOXO6, whereas the knockdown of FOXO6 increased
the association of HDAC3 with the C-myc promoter. Consistently,
the overexpression of FOXO6 resulted in markedly more acetyla-
tion of histone 3 at Lys4 and Lys9 (Ac-H3K4 and Ac-H3K9), two
Fig. 4. FOXO6 trans-activates C-myc expression independent of its DNA binding domain. (A) SNU-16 cells were co-transfected with the wild-type FOXO6 or FOXO6 with DNA
binding domain deﬁciency (FOXO6-DBD del) together with human C-myc luciferase promoter (1200 bp  +1 bp) and the luciferase activity was measured after co-
transfection for 36 h. The transcription start site was considered as +1 bp. ⁄⁄P < 0.001 compared with empty vector (Ctrl). (B and C) mRNA (B) and protein (C) levels of C-myc
were analyzed by Real-time PCR or Western blot in SNU-16 cells transfected with empty vector (Ctrl), FOXO6 or FOXO6-DBD del for 24 or 48 h, respectively. ⁄⁄⁄P < 0.001
compared with empty vector (Ctrl). (D) SNU-16 cells were co-transfected with series of C-myc promoter as indicated. ⁄⁄⁄P < 0.001 compared with empty vector (Ctrl). (E) SNU-
16 cells were co-transfected with the wild-type C-myc promoter (WT) or HNF4 binding site mutant promoter (Mut) together with empty vector (Ctrl) or HNF4. The luciferase
activity was measured after co-transfection for 36 h. ⁄⁄⁄P < 0.001 compared with mutant promoter. (F) SNU-16 cells were co-transfected with the wild-type C-myc promoter
(WT) or HNF4 binding site mutant promoter (Mut) together with empty vector (Ctrl), HNF4, FOXO6 or FOXO6 plus HNF4. The luciferase activity was measured after co-
transfection for 36 h. ⁄⁄⁄P < 0.001 compared with mutant groups. (G) SNU-16 cells were co-transfected with the wild-type C-myc promoter together with empty vector (Ctrl)
or FOXO6. Cells were pre-transfected with siRNA oligos targeting HNF4 or scramble siRNA (Ctrl siRNA) for 24 h. ⁄⁄⁄P < 0.001 compared with other two groups. (H and I) mRNA
(H) and protein (I) levels of C-myc were analyzed by Real-time PCR or Western blot in SNU-16 cells transfected with empty vector (Ctrl) or FOXO6 for 24 or 48 h, respectively.
Cells were pre-transfected with siRNA oligos targeting HNF4 or scramble siRNA (Ctrl siRNA) for 24 h. ⁄⁄⁄P < 0.001 compared with other two groups.
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(Fig. 5H). Moreover, although the mRNA and protein levels of
HNF4 were not changed between normal and gastric cancer tissues
(Supplementary Fig. 4A and B), the association of HNF4 with the C-
myc promoter was signiﬁcantly increased in tumor tissues (Fig. 5I).
Taken together, these data indicate that by interacting with HNF4,
FOXO6 strengthens the association of HNF4 with the C-myc pro-
moter and increases histone acetylation to trans-activate C-myc
expression (Fig. 5J). Consistently, we found that mRNA levels of
C-myc were elevated in gastric cancer tissues (Supplementary
Fig. 5A). Moreover, correlation analysis revealed a signiﬁcant posi-
tive correlation between mRNA levels of FOXO6 and C-myc, further
conﬁrming the roles of FOXO6 on the regulation of C-myc (Supple-
mentary Fig. 5B).
4. Discussion
The c-myc oncoprotein, as a transcription factor, is a master
regulator of genes involved in diverse cellular processes [21]. Situ-
ated upstream of signalling pathways regulating cellular replica-
tion/growth as well as apoptosis/growth arrest, C-myc may help
integrate processes determining cell numbers and tissue size in
physiology and disease [21]. In cancer, c-myc acts as oncogenicroles to promoter tumor formation in vivo and in vitro [21,22]. It
is now well established that the dys-regulated expression of c-
myc plays a signiﬁcant role in human cancer development [23].
Evidently, given that aberrant up-regulation of C-myc is present
in most, if not all, human cancers and is associated with a poor
prognosis [24]. Therefore, down-regulation of C-myc expression
or activity has been considered as a useful strategy for the control
of human cancers, including gastric cancers. For example, it was
shown that S-adenosylmethionine (SAM) can effectively inhibit
the growth of cancer cells by reversing the hypomethylation on
promoters of C-myc, thus down-regulating its expression in human
gastric cancer [25]. Besides, RAD001, an orally bioavailable deriva-
tive of rapamycin, markedly inhibited proliferation of human gas-
tric carcinoma cells by down-regulating expression of C-myc [26].
Although many down-stream target genes of C-myc have been
identiﬁed, the molecular networks controlling C-myc expression
remain largely unexplored.
In the present study, our data characterize FOXO6 as a novel
transcription factor that plays an important role in the develop-
ment of gastric carcinoma. FOXO6 expression, at the ﬁrst, was
shown to be up-regulated in gastric cancer tissues, although the
mechanisms leading to its overexpression will be investigated in
our further studies. Being classiﬁed to the FOXO family, FOXO6 is
Fig. 5. FOXO6 cooperates HNF4 to transactivate C-myc expression. (A and B) Immunoblot (IB) showing coprecipitation of HNF4 (A) or FOXO6 (B) upon immunoprecipitation
(IP) of FOXO6 (A) or HNF4 (B) in nuclear extracts from SNU-16 cells. Anti-IgG was used as a negative control. (C) ChIP assays showing the binding of FOXO6 on the C-myc
promoter. SNU-16 cells were transfected with siRNA oligos targeting HNF4 or scramble siRNA (Ctrl) for 24 h. Then cells were ﬁxed with 1% formaldehyde and
immunoprecipitated with antibodies to IgG or FOXO6. ⁄⁄⁄P < 0.001 compared with scramble siRNA (Ctrl). (D) ChIP assays showing the binding of HNF4 on the C-myc promoter
in SNU-16 cells after transfection with empty vector or FOXO6 for 24 h. ⁄⁄⁄P < 0.001 compared with empty vector (Ctrl). (E) ChIP assays showing the binding of HNF4 on the C-
myc promoter in SNU-16 cells after transfection with siRNA oligos targeting HNF4 or scramble siRNA (Ctrl) for 24 h. ⁄⁄⁄P < 0.001 compared with scramble siRNA (Ctrl). (F) ChIP
assays showing the binding of HDAC3 on the C-myc promoter in SNU-16 cells after transfection with empty vector (Ctrl) or FOXO6 for 24 h. ⁄⁄⁄P < 0.001 compared with empty
vector (Ctrl). (G) ChIP assays showing the binding of HDAC3 on the C-myc promoter in SNU-16 cells after transfection with siRNA oligos targeting HNF4 or scramble siRNA
(Ctrl) for 24 h. ⁄⁄⁄P < 0.001 compared with scramble siRNA (Ctrl). (H) ChIP assays showing the binding of acetylated histone 3 lysine 4 and lysine 9 (Ac-H3K4 and Ac-H3K9) on
the C-myc promoter in SNU-16 cells after transfection with empty vector (Ctrl) or FOXO6 for 24 h. ⁄⁄⁄P < 0.001 compared with empty vector (Ctrl). (I) ChIP analysis of HNF4
binding to the C-myc promoter in normal or gastric cancer tissues. (n = 8). ⁄⁄⁄P < 0.001 compared with normal tissues. (J) Working model: In gastric cancer tissues, FOXO6
interacts with HNF4, promotes its association with the C-myc promoter and increases histone acetylation to trans-activate C-myc expression.
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the least homology (30%) in amino acid sequence with FOXO1, con-
tains only two Akt/PKB phosphorylation sites (Thr26 and Ser184),
and lacks the nuclear export signal, a structural motif that is con-
served in the carboxyl domain of other members of the FOXO fam-
ily. In addition, while FOXO1 acts as a tumor suppressor in many
tumor tissues [10–12], our data suggest that FOXO6 might be an
oncogene, which positively regulates cell proliferation. Indeed, as
shown in the Supplementary Fig. 6A–D, overexpression of FOXO1
inhibited proliferation of gastric cancer cells, while knockdown of
FOXO1 promoted it. Although the reason for this inconsistency be-
tween FOXO6 and other FOXO members remains unclear now, the
roles of FOXO6 in other tumors (hepatocyte carcinoma, colon can-
cer, etc.) remain to be explored in the future.
At the molecular level, our results demonstrated that FOXO6
could trans-activate C-myc expression in its DNA binding do-
main-independent manner. FOXO6 interacted with HNF4 and en-
hanced its association with C-myc promoter, which facilitates thehistone acetylation and increases mRNA transcription. Interest-
ingly, a recent study also indicates that FOXO1 could also regulate
cell proliferation independent of its transcriptional activity [27].
Therefore, together with this report, our study may broad the
knowledge of transcriptional regulatory roles of FOXO family.
However, further studies are still required to investigate more di-
rect and indirect target genes of FOXO6 in gastric cancer tissues.
Moreover, HNF4, classiﬁed as an orphan nuclear receptor, is en-
riched in liver tissues [28]. HNF4 is essential for the development
and maintenance of the hepatic epithelium and also has been asso-
ciated to several human diseases, including diabetes, colitis, and
cancer [29,30]. Interestingly, recent studies suggest that HNF4
exerts both tumor-promoting and tumor-suppressing roles in
hepatocyte carcinoma, while promotes intestinal cancer in mice
[31–33]. Therefore, its precise roles in cancer cell proliferation
and tumor formation remain to be deﬁned in other tumors.
Until now, little is known about the role of FOXO6 in gastric
cancer. Our results will provide another potential pathogenic
L. Qinyu et al. / FEBS Letters 587 (2013) 2105–2111 2111mechanism of gastric cancer, which may be useful for the develop-
ment of anti-gastric cancer therapeutics.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2013.
05.027.
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